Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

Autor: Mine Durusu Tanriover, Hamdi Levent Doğanay, Murat Akova, Hatice Rahmet Güner, Alpay Azap, Sıla Akhan, Şükran Köse, Fatma Şebnem Erdinç, Emin Halis Akalın, Ömer Fehmi Tabak, Hüsnü Pullukçu, Özgür Batum, Serap Şimşek Yavuz, Özge Turhan, Mustafa Taner Yıldırmak, İftihar Köksal, Yeşim Taşova, Volkan Korten, Gürdal Yılmaz, Mustafa Kemal Çelen, Sedat Altın, İlhami Çelik, Yaşar Bayındır, İlkay Karaoğlan, Aydın Yılmaz, Aykut Özkul, Hazal Gür, Serhat Unal, Bircan Kayaaslan, İmran Hasanoğlu, Ayça Dalkıran, Ömer Aydos, Güle Çınar, İrem Akdemir-Kalkan, Ahmet Çağkan İnkaya, Mehtap Aydin, Hatice Çakir, Jale Yıldız, Özenir Kocabıyık, Sonay Arslan, Bayram Nallı, Ömer Demir, Sarp Singil, Çiğdem Ataman-Hatipoğlu, Günay Tuncer-Ertem, Sami Kınıklı, Uğur Önal, Bilgül Mete, Gözde Dalgan, Meltem Taşbakan, Tansu Yamazhan, Berna Kömürcüoğlu, Enver Yalnız, Aysun Benli, Çağla Keskin-Sarıtaş, Mustafa Gökhan Ertosun, Özlenen Özkan, Salih Emre, Seçil Arıca, Ferit Kuşçu, Aslıhan Candevir, Buket Ertürk-Şengel, Fadime Ayvaz, Firdevs Aksoy, Çiğdem Mermutluoğlu, Yakup Demir, Gülşah Günlüoğlu, Seda Tural-Önür, Ayşin Kılıç-Toker, Esma Eren, Barış Otlu, Ayşe Özlem Mete, Kübra Koçak, Hale Ateş, İlkay Koca-Kalkan, Kurtuluş Aksu

Publikováno v: Lancet (London, England)

Background CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years and older in phase 1/2 trials, and provided a good humoral response against SARS-CoV-2.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c968a18aabe68eea102421fdd0bbec9c
http://europepmc.org/articles/PMC8266301